Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated.

Published byBlanca Castillo Modified over 5 years ago

Similar presentations

Presentation on theme: "Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated."— Presentation transcript:

1 Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated with Mycophenolate Mofetil  Hong Li, Donald E. Mager, Brenda M. Sandmaier, Barry E. Storer, Michael J. Boeckh, Meagan J. Bemer, Brian R. Phillips, Linda J. Risler, Jeannine S. McCune  Biology of Blood and Marrow Transplantation  Volume 20, Issue 8, Pages (August 2014) DOI: /j.bbmt Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Final pharmacokinetic model characterizing total MPA, unbound MPA, and total MPAG concentrations following oral MMF administration. tlag, lag time; GI, gastrointestinal tract; ka, first-order absorption rate constant; fu, fraction unbound of MPA; Vc, volume of central compartment of total MPA; Q, intercompartment clearance of total MPA; Vp, volume of peripheral compartment of total MPA; CLMPA, clearance of total MPA; CLMPAG, clearance of total MPAG; Vm, volume of central compartment of total MPAG; k41, first-order rate constant of EHC. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Interpatient variability in IMPDH activity in PMNCs on day +21. Concentration-response of IMPDH activity by total MPA (A) and unbound MPA (B) plasma concentrations. Time course of IMPDH activity and total MPA concentration (mean ± SD) (C). Percentage of IMPDH activity (mean ± SD) vs. total MPA corrected for baseline (ie, predose) values (D). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Association of IMPDH AUEC (pmol × 106 cells) with acute GVHD (A), CMV reactivation (B), nonrelapse mortality (C), and overall mortality (D) in 45 patients receiving an unrelated donor graft. Only events on or after day +26 are included. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 Visual representation of IMPDH AUEC (gray area, in units of pmol × 106 cells) after a single dose of MMF at steady state (A) and distribution of IMPDH AUEC in all patients (B). Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated."

Similar presentations

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.
Volume 85, Issue 6, Pages (June 2014)

Volume 85, Issue 6, Pages (June 2014)
Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,
A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease  Paul A. Carpenter,

A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease  Paul A. Carpenter,
Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation 

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation 
Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.
Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:
Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplantation Recipients 

Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplantation Recipients 
Keratinocyte Dysplasia in Hematopoietic Stem Cell Transplantation Recipients in the Day-28-to-84 Posttransplantation Period  Ning Li, Katherine A. Guthrie,

Keratinocyte Dysplasia in Hematopoietic Stem Cell Transplantation Recipients in the Day-28-to-84 Posttransplantation Period  Ning Li, Katherine A. Guthrie,
Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.
Danielle M. Zerr, Michael Boeckh, Colleen Delaney, Paul J

Danielle M. Zerr, Michael Boeckh, Colleen Delaney, Paul J
Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source  Sharat Damodar,

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source  Sharat Damodar,
Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Similar presentations

Ads by Google